Gonorrhea Therapeutics Market Size, Share, Growth, Trends, Consumption, Revenue, Company Analysis and Forecast 2020-2027

The global gonorrhea therapeutics market size surpassed at US$ 1.4 Bn in 2019 and to reach US$ 2 billion by 2027 with a CAGR of 5.1% from 2020 to 2027.

Why Partnerships with Hospital Pharmacies Could be Profitable

The sales of gonorrhea therapeutics are projected to witness significant uptake from hospital pharmacies, as hospitals remain preferred care centers for patients diagnosed with gonorrhea. According to TMR’s estimates, hospital pharmacies will account for a value tantamount to ~US$ 548 Mn in 2019, out of which, ~37% of sales will come from hospital pharmacies based in North America alone.

Propitious environment for the growth of the healthcare sector in North America that is attributable to the intervention of the government in creating awareness regarding the prevalence of diseases, and hefty financial allocations for R&D activities are also likely to reflect on the advancement of the gonorrhea therapeutics market. Currently, North America monopolizes the gonorrhea therapeutics market; however, the Asia Pacific market holds profitable prospects on account of the growing sprawl of bacterial infections. On top of it, improvements in healthcare infrastructure coupled with financial lucidity of individuals has encouraged a large base to opt for effective gonorrhea therapeutics.

Drivers & Restraints

• Rising Prevalence of Gonorrhea: Gonorrhea is the second-most commonly reported notifiable disease in the U.S. Infections due to Neisseria gonorrhea, such as those resulting from Chlamydia trachomatis, are a major cause of pelvic inflammatory disease (PID) in the U.S. Moreover, epidemiologic and biologic studies provide evidence that gonococcal infections facilitate the transmission of HIV infection.
• Emergence of Antibiotic-Resistant Gonococcal Strain: CDC data highlights the rising resistance to one of the two antibiotics in the dual therapy for gonorrhea, a development that threatens the last remaining effective treatment for the disease. N. gonorrhea has progressively developed resistance to each of the antimicrobials used for the treatment of gonorrhea. Declining susceptibility to cefixime resulted in a change to the CDC treatment guidelines in 2015, so that dual therapy with ceftriaxone and azithromycin is presently the only CDC recommended treatment regimen for gonorrhea.

Overview

• Gonorrhea passes from person to person through unprotected oral, anal, or vaginal sex. People with numerous sexual partners or those who don’t use a condom are at a significantly high risk of infection. The best protection against infection includes abstinence, monogamy (sex with only one partner), and proper condom usage. Behaviors that make a person more likely to engage in unprotected sex also increase the likelihood of infection. These behaviors include alcohol abuse and illegal drug abuse, particularly intravenous drug use.
• Symptoms usually occur within two to 14 days after exposure. However, some people infected with gonorrhea never develop noticeable symptoms. It’s important to remember that, a person with gonorrhea who doesn’t exhibit symptoms, also called a nonsymptomatic carrier, is still contagious. People are more likely to spread the infection to other partners when they don’t have noticeable symptoms.
• Healthcare professionals can diagnose a gonorrhea infection in several ways. They can obtain a sample of fluid from the symptomatic area with a swab (penis, vagina, rectum, or throat) and place it on a glass slide. If the doctor suspects a joint or blood infection, the sample is obtained by drawing blood or inserting a needle into the symptomatic joint to withdraw fluid. Subsequently, a stain is added to the sample and examined under a microscope. A gonorrhea infection is confirmed if the cells react to the stain. This test may also be carried out by a lab technologist.

Rising Prevalence of Gonorrhea and Use of New Diagnostic Tests to Drive Market Growth

The diagnosis of gonorrhea is an ongoing challenge. Gonorrhea is the second-most commonly reported notifiable disease in the U.S. Infections due to Neisseria gonorrhea, such as those resulting from chlamydia trachomatis, are a major cause of pelvic inflammatory disease (PID) in the U.S. Moreover, epidemiologic and biologic studies provide evidence that gonococcal infections facilitate the transmission of HIV infection.

Gonorrhea is a common bacterial sexually transmitted disease (STD) that can cause serious complications if not detected and treated. Gonorrhea testing identifies if the bacteria Neisseria gonorrhea is the cause of a person's infection. Screening, for diagnosing, and treating gonorrhea is highly important to prevent long-term complications and spread of the infection.

Numerous tests available to detect gonococcal infection mostly require laboratory facilities, and hence, are expensive. Tools for gonorrhea diagnosis include microscopy, culture, and various nonculture methods. Laboratory tests are highly sensitive; however, in practice, their high costs and technical requirements make their routine use difficult, and compromise their potential impact on STI control and management. Nevertheless, the increasing prevalence of gonorrhea and the advent of new diagnostic tests are expected to drive the growth of the gonorrhea therapeutics market.

Uncomplicated Gonococcal Infection Type to Dominate Gonorrhea Therapeutics Market

• In terms of product, the global gonorrhea therapeutics market has been classified into uncomplicated gonococcal infection, gonococcal arthritis, gonococcal meningitis, and endocarditis. The uncomplicated gonococcal infection segment dominated the global gonorrhea therapeutics market in 2019, and the trend is likely to continue during the forecast period.

Hospitals Pharmacies Promising Distribution Channel

• In terms of distribution channel, the global gonorrhea therapeutics market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. 
• The hospitals pharmacies segment is expected to be a highly lucrative segment of the global gonorrhea therapeutics market during the forecast period. The hospitals pharmacies segment dominates the gonorrhea therapeutics market due to the number of diagnostics test available.

North America a Prominent Gonorrhea Therapeutics Market

• In terms of region, the global gonorrhea therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
• North America dominated the global gonorrhea therapeutics market in 2019, followed by Europe. According to recent studies conducted by WHO, in the U.S. alone, 1 million cases of gonorrhea are reported annually. Favorable reimbursement policies and government funding to numerous health organizations for the development of drug-resistant gonorrhea treatment are likely to be key drivers of the gonorrhea therapeutics market in North America.
• Europe follows North America in terms of share of the global gonorrhea therapeutics market. The region accounted for a major share of the global gonorrhea therapeutics market in 2019, owing to the increasing incidence of gonococcal infection in the region. Gonorrhea is the second-most reported sexually transmitted infection in Europe, after chlamydia.

Growth Strategies by Key Players in the Gonorrhea Therapeutics Market

• The global gonorrhea therapeutics market is fragmented in terms of number of players. Key players operating in the global gonorrhea therapeutics market include GlaxoSmithKline plc. Merck & Co., Inc., Pfizer Inc, AstraZeneca, Hologic, Inc., Danaher, Abbott, Becton Dickinson and Company, and F. Hoffmann-La Roche Ltd.
• Research & development carried out by key players is governed by state organizations that support and finance applied research and experimental development.
• Wide distribution network, new product development, and mergers & acquisitions are key strategies followed by these major players in order to consolidate their position in the global gonorrhea therapeutics market.

Market Segmentation

By Gonococcal Infection

• Uncomplicated Gonococcal Infection
• Gonococcal Arthritis
• Gonococcal Meningitis
• Endocarditis

Bby Treatment

• Monotherapy
• Dual Therapy

By Route of Administration

• Oral
• Injectable

By Gender

• Men
• Women

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • Australia
  • India
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Israel
  • Rest of Middle East & Africa

Scope of the Study

[200 Pages Report] Vision Research Reports, in its latest business study, identifies significant growth opportunities present in the gonorrhea therapeutics market for the forecast period of 20209-2027. The comprehensive business study traces significant trends and recent developments encircling the gonorrhea therapeutics landscape. In addition, it provides intelligent industry insights into the gonorrhea therapeutics market by lending an incisive assessment of the key drivers, restraints, threats, and opportunities.

This comprehensive business study offers a detailed assessment of the demand and supply chain in the gonorrhea therapeutics market. This exclusive guide determines the macroeconomic as well as microeconomic parameters that help in comprehending the growth of the gonorrhea therapeutics market during the forecast period.

The gonorrhea therapeutics market size has been evaluated in terms of value (US$ Mn). Information included in this exhaustive research report can aid stakeholders in the gonorrhea therapeutics market in determining profitable growth opportunities for their business advancement.

This exclusive research report also uncovers an in-depth SWOT assessment of the leading, prominent, and emerging market players operating in the gonorrhea therapeutics market. This assessment will aid stakeholders gain an incisive perspective apropos of the growth of the gonorrhea therapeutics market.

This in-depth business guide assesses and includes Porter’s Five Forces to provide key growth strategies present in the gonorrhea therapeutics market during the forecast period. This exclusive guide provides key information about the competition present in the gonorrhea therapeutics market by identifying key competitors. The exclusive report also includes key strategies, financials, and notable developments present in the gonorrhea therapeutics market during the forecast period of 2019-2027.

Key Questions Answered

An exclusive business study published by Vision Research Reports(VRR) offers intelligent insights apropos of the growth of the gonorrhea therapeutics market, through which stakeholders operating in the market can gain an edge over their competitors. Authors of the report assess the gonorrhea therapeutics market, and provide data and numbers demonstrating the impact of the influential trends and key developments in the industry. The global study addresses the key questions of stakeholders in the gonorrhea therapeutics market.

• What are the recent developments and market shifts observed in the gonorrhea therapeutics market?
• What are the key winning imperatives for leading and prominent players functioning in the gonorrhea therapeutics market?
• What are the significant trends stimulating the growth of the gonorrhea therapeutics market?
• Which distribution channel will draw significant sales in the gonorrhea therapeutics market?

 Research Methodology

Research carried out by analysts at VRR includes a robust research approach that includes both, primary and secondary research. In order to carry out primary research, discussions were scheduled with distributors, industry experts, vendors, and key opinion leaders. This significantly helps in assessing the demand-supply gap in the gonorrhea therapeutics market.

For carrying out secondary research, company websites, marketing collaterals, press releases, industry associations, and statistics presented by government websites were referred to.